LENZ Therapeutics, Inc.
About LENZ Therapeutics, Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $19.1M
- Net income
- -$82.1M
- Total assets
- $305.9M
- Market cap
- $219.8M
- Gross margin
- 97.8%
- Operating margin
- -477.5%
- Net margin
- -430.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $19.1M
- Cost of revenue
- $418.0K
- Gross profit
- $18.7M
- Operating expenses
- $109.8M
- Operating income
- -$91.1M
- Income tax
- $502.0K
- Net income
- -$82.1M
- EPS (basic)
- $-2.85
- EPS (diluted)
- $-2.85
Balance sheet
- Total assets
- $305.9M
- Current assets
- $301.4M
- Total liabilities
- $21.5M
- Current liabilities
- $21.2M
- Shareholders’ equity
- $284.3M
Cash flow
- Operating cash flow
- -$69.2M
- Investing cash flow
- -$75.7M
- Financing cash flow
- $149.7M
- Net cash flow
- $4.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $219.8M
- EPS (diluted)
- $-2.85
- Shares outstanding
- 32.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 22, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $82.1M in FY2025.
- Gross margin of 97.8%, net margin -430.3%.
- Trading 86% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review LENZ Therapeutics, Inc..
Write a review
News about LENZ Therapeutics, Inc.
News & sentiment via Polygon.io
